We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-10.34%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.07B
AUM Growth
-$1.75B
(-62%)
Cap. Flow
-$771M
Cap. Flow
% of AUM
-72.36%
Top 10 Holdings %
Top 10 Hldgs %
79.25%
Holding
36
New
4
Increased
1
Reduced
17
Closed
11
Avg Time Held Equity + Options
8.8
quarters
Top 10 Avg Time Held Equity + Options
3.3
quarters
Top 20 Avg Time Held Equity + Options
6.2
quarters
Avg Time Held Equity only
9.3
quarters
Top 10 Avg Time Held Equity only
3.1
quarters
Top 20 Avg Time Held Equity only
7.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$42.6M |
| 2 |
Merck
MRK
|
+$39.7M |
| 3 |
UnitedHealth
UNH
|
+$38.2M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$15.7M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$5.89M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$121M |
| 2 |
Humana
HUM
|
+$106M |
| 3 |
Baxter International
BAX
|
+$87.9M |
| 4 |
CVS Health
CVS
|
+$78.7M |
| 5 |
PTC Therapeutics
PTCT
|
+$76.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.39% |
| 2 | Miscellaneous | 32.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$822B
| $309M | 29% |
500,000
-1,000,000
| -67% | -$572M |
2023 Q4
6 quarters
|
|
|
2
Zimmer Biomet
ZBH
$17.6B
| $91.2M | 8.56% |
1,000,000
-1,250,000
| -56% | -$121M |
2021 Q3
15 quarters
|
|
|
3
Baxter International
BAX
$12.9B
| $86.3M | 8.1% |
2,850,000
-2,900,000
| -50% | -$87.9M |
2023 Q1
9 quarters
|
|
|
4
Humana
HUM
$50.5B
| $73.3M | 6.89% |
300,000
-425,000
| -59% | -$106M |
2024 Q2
4 quarters
|
|
|
5
CVS Health
CVS
$112B
| $72.4M | 6.8% |
1,050,000
-1,200,000
| -53% | -$78.7M |
2024 Q2
4 quarters
|
|
6
Globus Medical
GMED
$10.2B
| $47.2M | 4.43% |
800,000
-450,000
| -36% | -$29.1M |
2023 Q1
9 quarters
|
|
|
7
Icon
ICLR
$12.7B
| $43.6M | 4.1% |
+300,000
| New | +$42.6M |
2025 Q2
0 quarters
|
|
8
Ascendis Pharma A/S
ASND
$14.7B
| $43.1M | 4.05% |
250,000
-100,000
| -29% | -$16.3M |
2024 Q3
3 quarters
|
|
|
9
Merck
MRK
$350B
| $39.6M | 3.72% |
+500,000
| New | +$39.7M |
2025 Q2
0 quarters
|
|
10
CALL
GSK
GSK
$92.7B
| $38.4M | 3.6% |
1,000,000
| – | – |
2024 Q4
2 quarters
|
|
11
Pfizer
PFE
$162B
| $36.4M | 3.41% |
1,500,000
-1,000,000
| -40% | -$23.3M |
2024 Q4
2 quarters
|
|
|
12
BioMarin Pharmaceuticals
BMRN
$10.5B
| $33M | 3.1% |
600,000
+100,000
| +20% | +$5.89M |
2024 Q4
2 quarters
|
|
|
13
UnitedHealth
UNH
$339B
| $31.2M | 2.93% |
+100,000
| New | +$38.2M |
2025 Q2
0 quarters
|
|
14
Viatris
VTRS
$19.8B
| $24.6M | 2.31% |
2,750,000
-4,750,000
| -63% | -$40.2M |
2015 Q3
39 quarters
|
|
15
Brookdale Senior Living
BKD
$2.42B
| $15M | 1.4% |
2,150,000
-4,100,000
| -66% | -$26.7M |
2015 Q4
38 quarters
|
|
16
DELISTED
ZimVie
ZIMV
| $15M | 1.4% |
1,600,000
-285,000
| -15% | -$2.6M |
2022 Q1
13 quarters
|
|
|
17
DELISTED
Apellis Pharmaceuticals
APLS
| $14.7M | 1.38% |
+850,000
| New | +$15.7M |
2025 Q2
0 quarters
|
|
18
Myriad Genetics
MYGN
$390M
| $10.6M | 1% |
2,000,000
-350,000
| -15% | -$2.07M |
2019 Q3
23 quarters
|
|
19
Evolent Health
EVH
$520M
| $9.57M | 0.9% |
850,000
-2,150,000
| -72% | -$19.7M |
2024 Q2
4 quarters
|
|
20
Concentra Group Holdings
CON
$4.79B
| $8.23M | 0.77% |
400,000
-1,200,000
| -75% | -$25.6M |
2024 Q3
3 quarters
|
|
21
Inogen
INGN
$168M
| $6.85M | 0.64% |
975,000
| – | – |
2021 Q4
14 quarters
|
|
22
Denali Therapeutics
DNLI
$2.94B
| $5.6M | 0.53% |
400,000
-850,000
| -68% | -$12M |
2024 Q1
5 quarters
|
|
23
DELISTED
Theravance Biopharma
TBPH
| $4.96M | 0.47% |
450,000
-550,000
| -55% | -$5.35M |
2024 Q1
5 quarters
|
|
24
AnaptysBio
ANAB
$1.36B
| $2.77M | 0.26% |
125,000
-625,000
| -83% | -$13.1M |
2024 Q4
2 quarters
|
|
25
OraSure Technologies
OSUR
$263M
| $2.7M | 0.25% |
900,000
| – | – |
2020 Q3
19 quarters
|
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Camber Capital Management held 36 positions worth $1.07B, down 62% from $2.81B the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Camber Capital Management withdrew a net $771M in Q2 2025, closing 11 positions and reducing 17 holdings. Its most notable exit was PTC Therapeutics, an estimated $76.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 57% a quarter earlier, followed by Miscellaneous.
Against the trend, Camber Capital Management opened a new position in Icon worth $43.6M.
- Camber Capital Management's largest Q2 2025 buy was Icon: 300,000 shares worth $43.6M.
- Camber Capital Management added most to BioMarin Pharmaceuticals in Q2 2025, an estimated $5.89M increase.
- Camber Capital Management's biggest Q2 2025 reduction was Zimmer Biomet, cutting an estimated $121M.
- Camber Capital Management fully exited PTC Therapeutics in Q2 2025, selling an estimated $76.4M.
- Camber Capital Management's ten largest holdings make up 79% of its $1.07B portfolio in Q2 2025.
- Camber Capital Management opened 4 new positions and closed 11 in Q2 2025.
- Camber Capital Management's portfolio value fell 62% quarter-over-quarter to $1.07B.
Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.